Developing Bromodomain and ExtraTerminal (BET) Protein Inhibitors

ConverGene is an early-stage biopharmaceutical company focusing on the discovery and development of novel cancer drugs targeting the root regulatory mechanisms within cancer cells. Our primary goal is the development of small-molecule drugs that target bromodomains, a well-characterized structural feature of proteins which mediate epigenetic changes in DNA and DNA-packaging proteins. 

ConverGene’s first product development focus is its BET inhibitor program to treat hematological cancers including acute myeloid leukemia (AML) and multiple myeloma (MM). These hematological cancer indications were selected because of i) strong scientific evidence that BET inhibitors will be clinically active; ii) significant unmet medical needs; and iii) orphan disease status, yet represent a significant market size.

Inhibition of BRD4 Suppresses MYC

Despite extensive understanding of MYC and the knowledge that MYC is critical to the generation and maintenance of malignancies, drugs directly targeting the MYC protein have not been developed because MYC lacks clear domains that can be exploited as drug binding sites.

However, inhibition of BRD4 was recently shown to directly suppress the MYC oncogene, one of the most over-expressed, well studied, and important control switch genes that drive human cancers.

News & Events
ConverGene scientists in conjunction with University of Maryland Baltimore researchers design new class of dual BET/PLK1 inhibitors.  
Citation:  ACS Med Chem Lett. 2015 May 18;6(7):764-9. 
doi: 10.1021/acsmedchemlett.5b00084. eCollection 2015.

ConverGene receives $25,000 IMPACT grant award from the Montgomery County Department of Economic Development to further the progress of its BET inhibitor program. 

ConverGene executives attend the EpiGenetics Congress July 21-23, 2015 in Boston. 

ConverGene executives attend the BIO International Convention June 15-18, 2015 in Philadelphia.   

ConverGene executives attend the Epigenetics and Cancer Conference January 25-30, 2015 in Keystone, Colorado.

ConverGene executives attend the Discovery on Target meeting October 8-10, 2014 in Boston.

ConverGene selected to receive a Maryland Industrial Partnership (MIPS) Award (MIPS).   The funds will be used for the development of a bromodomain inhibitor. 

ConverGene executives attend Bio2014 June 23-26, 2014 in San Diego.

ConverGene executives attend the International Molecular Medicine Tri-Conference February 9-14, 2014 in San Francisco .

ConverGene raises $850,000 in the latest round of seed investment, bringing the total capital raised to $1.1 million.

ConverGene receives $75,000 TEDCO grant to broaden medicinal chemistry efforts in partnership with the University of Maryland.

ConverGene enters into a Lease and Master Services Agreement with Noble Life Sciences, Inc., a Montgomery County, Maryland-based preclinical drug development services company. Noble provides infrastructure, laboratory, and R&D services, to ConverGene.